EQRx, Inc.
DelistedCIK 1843762fmd_1Z37WPG2ZFD1HQVYRRYD7YHQXPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2023, 12 periods
| Line item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Realized investment gains (losses) | – | – | 0 |
| Research and development | 224 | 118 | 228 |
| Total operating expenses | 250 | 196 | 356 |
| Operating income | (250) | (196) | (356) |
| Other non-operating income (expense) | 0 | 96 | 187 |
| Income before taxes | (250) | (100) | (169) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (250) | (100) | (169) |
| Net income | (250) | (100) | (169) |
| Net income to common shareholders | (250) | (100) | (169) |